Forward looking statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Example
Slide 3: 2009-2010 corporate goals
2009-2010 corporate goals RGN clinical trials in 2009-2010 Epidermolysis Bullosa (EB) Phase 2 derma previously targeted for early 2010 completion Ophthalmic "compassionate use" data previously targeted for Q3 2009 Ophthalmic Phase 2 trial initiation previously targeted for 2010 Parenteral (injectabl
Slide 4: 2009-2010 corporate goals - report
2009-2010 corporate goals - report RGN clinical trials in 2009-2010 Ophthalmic compassionate use data previously targeted for Q3 2009 - Completed Ophthalmic Phase 2 trial initiation targeted for 2010 - Still on target Parenteral (injectable) Phase 2 cardiovascular trial initiation targeted for 2010
Slide 5: Other events in 2009-2010
Other events in 2009-2010 RGN awarded $3 million grant from NIH for AMI studies New neurological data resulting from MTA with Henry Ford Hospital: Researchers published three major papers published in Neuroscience and the Journal of Neurosurgery showing T^4's ability to reduce inflammation, promote
Slide 6: Clinical goals for 2010-2011
Clinical goals for 2010 -2011 First Patient In Phase 2 Dry Eye trial Q3 2010 First Patient In Phase 2 AMI trial Q4 2010 Initiation of Phase 1/2 MS trial Q4 2010 First Patient In Phase 1/2 MS trial Q1 2011 Completion of Phase 2 EB trial Q2 2011 Data from Dry Eye and AMI trials 2011 Preliminary data f
Slide 7: Financial & IR goals in 2010-2011
Financial & IR goals in 2010 -2011 Apply for $4.5 million from Health Care Reform Act Jul 21, 2010 Non-dilutive funding Maximum award is $5 million per company Highly competitive and paid out in two tranches Q4 2010 & Q1 2011 Evaluating other grant opportunities Rodman & Renshaw Conference Sep 12-15
Slide 8: RGN product candidates
Cardiovascular & CNS RGN-352 (injectable for acute myocardial infarction, MS, stroke) About the cover - July 2, 2009 "... The cover image, by Paul R. Riley, illustrating a heart wrapped in a layer of regenerating cells, is from a study showing that thymosin ^4 guides progenitor cells from the outer
Slide 9: Product candidates time-lines
Product candidates time-lines Preclinical RGN-137 Topical Phase 3 Phase 2 Phase 1 Pharmaceutical Product Candidates Acute Myocardial Infarction RGN-457 Inhalation Cosmeceutical Peptides RGN-259 Eye drops R & D Partnering/ Marketing Formulation, Tox & Clinical Testing In Vitro Testing Cosmeceutical P
Slide 10: RegeneRx Product/Patients U.S.
RegeneRx Product/Patients U.S. Product Disease US treatable population/yr RGN-137 EB 12K RGN-259 Sjogren's Dry Eye 3,000K Neurotrophic Keratitis 4K GVHD 3K RGN-352 AMI 650K MS 300K Ischemic Stroke 700K Crohn's 125K Ulcerative Colitis 158K RGN-457 Cystic Fibrosis 30K Bronchiectasis 81K
Slide 11: Research and Development - active collaborations
Research and Development - 25 active collaborations* Midwest Hospital Center (DM) Neurologic and stroke European Research Center (EG) Neurologic and stroke U.S. Military (JG) Ophthalmic repair post-exposure to chemical agents European University (BP) Stem cell - cardiovascular New England University
Slide 12: Selected financial data
Selected financial data NYSE Amex symbol: RGN Cash (6/30/10) $6.5 M Shares outstanding 75.5 M Fully diluted shares 92.4 M Share price (6/30/10) $0.27 52-week price range $0.23 - $1.95 Market capitalization (6/30/10) $20 M
Slide 13: Summary
Summary Newly published studies show T^4's significant effects in multiple sclerosis, stroke, and traumatic brain injury models RGN clinical trial targets in 2009-2010 Dry Eye physician-sponsored Phase 2 trial targeted for Q3 2010 AMI Phase 2 AMI trial initiation targeted for Q4 2010 Epidermolysis B